Discovering the AMPLITUDE-Of Efpeglenatide
hosted byConnect Educate Impact (CEI)
Discovering the AMPLITUDE-Of Efpeglenatide is organized by Connect Educate Impact (CEI).
Initial Release Date: June 8, 2022
Planned Expiration Date: June 8, 2025
Description:
The AMPLITUDE-O trial evaluated the cardiovascular and renal outcomes of efpeglenatide in patients with type 2 diabetes. This Journal Club CE discusses the trial and whether efpeglenatide extends similar protective cardiovascular and renal effects as already existing GLP-1 receptor agonists.
Objectives:
Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
• Compare and contrast the mechanism of action of efpeglenatide versus other GLP-1 agonists.
• Discuss how the outcomes of the AMPLITUDE-O trial were incorporated into the Standards of Medical Care in Diabetes-2022.
• Interpret the safety and efficacy data on efpeglenatide's effect on cardiovascular and renal outcomes in the AMPLITUDE-O trial
• Evaluate the strengths and limitations of the AMPLITUDE-O trial
• Evaluate efpeglenatide's place in therapy for the care of a patient with Type 2 Diabetes.
